New cytotoxic agents: a review of the literature.
作者： Katsuyuki Hotta , Hiroshi Ueoka
DOI: 10.1016/J.CRITREVONC.2005.01.006
关键词:
摘要: The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction many cytotoxic agents during past decade, only modest improvement in survival has been achieved. In order urgently improve these situations, new as well molecular-targeted are now under investigation. this article, we reviewed latest information regarding antitumor activity, toxicity, pharmacokinetics, clinical application agents.
elsevier.com
sci-hub.se 参考文章(162)
K. Oesterlind, J. M. Sanchez, P. Zatloukal, M. C. Perry, J. T. Hamm, C. P. Belani, E. S. Kim, J. F. Vansteenkiste, E. Felip, M. Berton, A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. ,vol. 22, pp. 7248- 7248 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.7248
William J. Berg, Lawrence Schwartz, Richard Yu, Madhu Mazumdar, Robert J. Motzer, Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Investigational New Drugs. ,vol. 19, pp. 317- 320 ,(2001) , 10.1023/A:1010609810517
A. Hussain, R. S. Dipaola, A. D. Baron, C. S. Higano, N. S. Tchekmediyan, J. A. Miller, J. D. Rothermel, A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC) Journal of Clinical Oncology. ,vol. 22, pp. 4563- 4563 ,(2004) , 10.1200/JCO.2004.22.90140.4563
David G. Pfister, John McCaffrey, Andrew J. Zahalsky, Gary K. Schwartz, Eric Lis, William Gerald, Andrew Huvos, Jatin Shah, Dennis Kraus, Ashok Shaha, Bhuvanesh Singh, Suzanne Wolden, Michael Zelefsky, Ilana Palgi, A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Investigational New Drugs. ,vol. 20, pp. 123- 127 ,(2002) , 10.1023/A:1014449309165
C. R. Becerra, C. Takimoto, J. A. Ajani, P. Major, K. Feit, A. Duggal, R. De Jagger, A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer Journal of Clinical Oncology. ,vol. 22, pp. 4126- 4126 ,(2004) , 10.1200/JCO.2004.22.90140.4126
B. Brockstein, B. Samuels, R. Humerickhouse, R. Arietta, P. Fishkin, J. Wade, J. Sosman, E.E. Vokes, Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Investigational New Drugs. ,vol. 19, pp. 249- 254 ,(2001) , 10.1023/A:1010628903248
T. Chen, A. Molina, S. Moore, S. Goel, K. Desai, A. Hamilton, T. Griffin, A. D. Colevas, S. Mani, F. Muggia, Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers Journal of Clinical Oncology. ,vol. 22, pp. 2115- 2115 ,(2004) , 10.1200/JCO.2004.22.90140.2115
R.G. Tozer, S. Burdette-Radoux, K. Berlanger, M.L. Davis, R.C. Lohmann, J.R. Rusthoven, N. Wainman, B. Zee, L. Seymour, A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Investigational New Drugs. ,vol. 20, pp. 407- 412 ,(2002) , 10.1023/A:1020694425356
A. C. Pavlick, M. Millward, K. Farrell, A. Hamilton, A. Broseus, N. Haas, T. Shore, A. Jacquotte, D. Colevas, F. Muggia, A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM) Journal of Clinical Oncology. ,vol. 22, pp. 7542- 7542 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.7542
Deborah K. Armstrong, John A. Blessing, Janet Rader, Joel I. Sorosky, A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study Investigational New Drugs. ,vol. 21, pp. 453- 457 ,(2003) , 10.1023/A:1026255403046